Repligen (NASDAQ: RGEN) reported Q2 EPS of $0.33, in-line with the analyst estimate of $0.33. Revenue for the quarter came in at $154 million versus the consensus estimate of $154.11 million.

GUIDANCE:

Repligen sees FY2024 EPS of $1.42-$1.49, versus the consensus of $1.45.

For earnings history and earnings-related data on Repligen (RGEN) click here.